瑞聲科技(2018.HK)領漲手機產業鏈股 獲小摩增持且花旗大肆上調目標價
格隆匯11月14日丨港股市場手機產業鏈股普漲,其中,瑞聲科技漲超4%,富智康集團和通達集團漲超3%,丘鈦科技、比亞迪電子和舜宇漲超1%。
花旗最新研報稱,瑞聲科技三季度業績超過預期,且目前市場低估了蘋果公司對瑞聲明年上半年業績的驅動,上調目標價50%至66港元。
另外,據港交所數據,2019年11月8日,瑞聲科技獲JP Morgan以每股均價52.3745港元,增持88.6萬股,總價約4640萬港元。增持後,JP Morgan持有權益的股份數目佔已發行的有投票權股份百分比為13.03%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.